DXCM Stock - DexCom, Inc.
Unlock GoAI Insights for DXCM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $4.03B | $3.62B | $2.91B | $2.45B | $1.93B |
| Gross Profit | $2.44B | $2.29B | $1.88B | $1.68B | $1.28B |
| Gross Margin | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% |
| Operating Income | $600.00M | $597.70M | $391.20M | $265.80M | $299.50M |
| Net Income | $576.20M | $541.50M | $341.20M | $216.90M | $493.60M |
| Net Margin | 14.3% | 14.9% | 11.7% | 8.9% | 25.6% |
| EPS | $1.46 | $1.44 | $0.88 | $0.56 | $1.31 |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Visit WebsiteEarnings History & Surprises
DXCMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $0.65 | — | — | — |
Q4 2025 | Oct 30, 2025 | $0.58 | $0.61 | +5.9% | ✓ BEAT |
Q3 2025 | Jul 30, 2025 | $0.44 | $0.48 | +8.2% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.33 | $0.32 | -2.2% | ✗ MISS |
Q1 2025 | Feb 13, 2025 | $0.48 | $0.45 | -6.1% | ✗ MISS |
Q4 2024 | Oct 24, 2024 | $0.44 | $0.45 | +2.3% | ✓ BEAT |
Q3 2024 | Jul 25, 2024 | $0.39 | $0.43 | +10.3% | ✓ BEAT |
Q2 2024 | Apr 25, 2024 | $0.27 | $0.32 | +18.5% | ✓ BEAT |
Q1 2024 | Feb 8, 2024 | $0.43 | $0.50 | +16.3% | ✓ BEAT |
Q4 2023 | Oct 26, 2023 | $0.34 | $0.50 | +47.1% | ✓ BEAT |
Q3 2023 | Jul 27, 2023 | $0.23 | $0.34 | +47.8% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $0.15 | $0.17 | +13.3% | ✓ BEAT |
Q1 2023 | Feb 9, 2023 | $0.26 | $0.34 | +30.8% | ✓ BEAT |
Q4 2022 | Oct 27, 2022 | $0.24 | $0.28 | +16.7% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $0.17 | $0.17 | 0.0% | = MET |
Q2 2022 | Apr 28, 2022 | $0.13 | $0.08 | -38.5% | ✗ MISS |
Q1 2022 | Feb 10, 2022 | $0.22 | $0.17 | -22.7% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $0.16 | $0.22 | +37.5% | ✓ BEAT |
Q3 2021 | Jul 29, 2021 | $0.11 | $0.19 | +72.7% | ✓ BEAT |
Latest News
Frequently Asked Questions about DXCM
What is DXCM's current stock price?
What is the analyst price target for DXCM?
What sector is DexCom, Inc. in?
What is DXCM's market cap?
Does DXCM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to DXCM for comparison